New drug aids individuals in losing almost 25% of their body weight

New Weight Loss Drug Shows Promise in Early Trials

In early stage 1A/2B trials, a new experimental weight loss drug demonstrated the potential to help individuals lose nearly 25% of their body weight.

Developed by Novo Nordisk, the drug known as Amuletin mimics amylin, a hormone that manages appetite, along with the Glucagon-like peptide 1 (GLP-1), which is the same hormone featured in medications like Ozempic and Wegovy. Martin Holst Lange, an executive at Novo Nordisk, mentioned that this is the first treatment combining two different biological pathways within a single molecule.

Pursuant to a Novo Nordisk announcement, a study involving 125 adults who were overweight or obese found that those receiving amuletin injections weekly lost more weight compared to those receiving a placebo. In fact, the high dose group (up to 60 mg) saw a weight reduction of approximately 24.3% after 36 weeks.

Earlier Phase 1 trials of the oral version of Amuletin revealed that it was “safe and acceptable,” with participants experiencing weight loss as opposed to those on a placebo. Daily pill intake resulted in around 10% weight loss, with an increase to 13% for those who took a double dose.

One interesting point noted by researchers is that participants on amuletin did not appear to encounter a “weight loss plateau.” They continued to shed pounds for as long as they used the medication. Agnes Gasoirek, a senior clinical pharmacology expert, remarked that the absence of stagnation in weight loss suggests further reductions are possible with extended use.

Novo Nordisk shared these findings at the American Diabetes Association meeting in Chicago and also included them in the medical journal Lancet. They expressed excitement over the results and the favorable feedback received from regulators, indicating plans to advance both subcutaneous and oral versions of the drug into phase 3 for weight management.

As with other GLP-1 medications, gastrointestinal side effects such as nausea and reduced appetite were common, although the researchers rated the serious adverse events as “mild to moderate.” It’s worth mentioning that increased doses tended to lead to more side effects, which makes it crucial for experts to monitor these reactions closely, especially since gastrointestinal issues are already prevalent in obese patients.

Dr. Christine Wren Field, an expert in bariatric surgery, commented on the promising initial outcomes, emphasizing that continued research is necessary to ensure that any therapeutic advantages surpass the risks, particularly in the context of long-term management.

While drugs based on GLP-1, including this experimental medication, hold potential, Dr. Wren also cautioned that such treatments shouldn’t be viewed as a standalone solution for obesity. She stated that obesity is a complex, multifaceted condition requiring a comprehensive and sustained approach. Pharmacological treatments can contribute, but they are usually more effective in tandem with other methods.